# EDGAR Filing Document

**Accession Number:** 0001464521
**File Stem:** 0001628280-25-039730
**Filing Date:** 2025-8
**Character Count:** 12732
**Document Hash:** cded97b915eb20e6e0f2b9708ff62980
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-039730.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001628280-25-039730

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250807

**FILED AS OF DATE**: 20250811

**DATE AS OF CHANGE**: 20250811

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tansey Casey M
- **CENTRAL INDEX KEY:** 0001474322

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42790
- **FILM NUMBER:** 251203690

**MAIL ADDRESS:**
- **STREET 1:** 1460 EL CAMINO REAL STE 100
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Heartflow, Inc.
- **CENTRAL INDEX KEY:** 0001464521
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 260506743
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0811

**BUSINESS ADDRESS:**
- **STREET 1:** 331 E EVELYN AVENUE
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94041
- **BUSINESS PHONE:** 650-241-1221

**MAIL ADDRESS:**
- **STREET 1:** 331 E EVELYN AVENUE
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94041

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cardiovascular Simulation, Inc.
- **DATE OF NAME CHANGE:** 20090519

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tansey Casey M<br><sub>(Last) (First) (Middle)</sub><br>C/O HEARTFLOW, INC.<br>331 E. EVELYN AVENUE<br><sub>(Street)</sub><br>MOUNTAIN VIEW, CA 94041<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Heartflow, Inc. [ HTFL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-08-11 |  | C |  | 3072759 | A | <sup>(1)(2)(3)(4)(5)</sup> | 3072759 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Common Stock | 2025-08-11 |  | C |  | 98303 | A | <sup>(1)(2)(3)(4)(5)</sup> | 98303 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Common Stock | 2025-08-11 |  | C |  | 16447 | A | <sup>(5)</sup> | 16447 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series B-1 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 220052<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 220052 | <sup>(1)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series B-1 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 330078<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 330078 | <sup>(1)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series B-1 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 10560<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 10560 | <sup>(1)</sup> | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Series B-1 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 7040<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 7040 | <sup>(1)</sup> | 0 | I | By USVP X Affiliates,  L.P.<sup>(6)</sup> |
| Series B-2 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 220052<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 220052 | <sup>(1)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series B-2 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 330078<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 330078 | <sup>(1)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series B-2 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 10560<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 10560 | <sup>(1)</sup> | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Series B-2 Preferred Stock | <sup>(1)</sup> | 2025-08-11 |  | C |  |  | 7040<sup>(1)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 7040 | <sup>(1)</sup> | 0 | I | By USVP X Affiliates,  L.P.<sup>(6)</sup> |
| Series C Preferred Stock | <sup>(2)</sup> | 2025-08-11 |  | C |  |  | 665623<sup>(2)</sup> | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 665623 | <sup>(2)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series C Preferred Stock | <sup>(2)</sup> | 2025-08-11 |  | C |  |  | 21295<sup>(2)</sup> | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 21295 | <sup>(2)</sup> | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Series D Preferred Stock | <sup>(3)</sup> | 2025-08-11 |  | C |  |  | 10106<sup>(3)</sup> | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 10106 | <sup>(3)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series D Preferred Stock | <sup>(3)</sup> | 2025-08-11 |  | C |  |  | 80855<sup>(3)</sup> | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 80855 | <sup>(3)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series D Preferred Stock | <sup>(3)</sup> | 2025-08-11 |  | C |  |  | 323<sup>(3)</sup> | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 323 | <sup>(3)</sup> | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Series D Preferred Stock | <sup>(3)</sup> | 2025-08-11 |  | C |  |  | 2586<sup>(3)</sup> | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 2586 | <sup>(3)</sup> | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Series F Preferred Stock | <sup>(4)</sup> | 2025-08-11 |  | C |  |  | 1164179<sup>(4)</sup> | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1164179 | <sup>(4)</sup> | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Series F Preferred Stock | <sup>(4)</sup> | 2025-08-11 |  | C |  |  | 37244<sup>(4)</sup> | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 37244 | <sup>(4)</sup> | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Convertible Promissory Note | $15.20 | 2025-08-11 |  | C |  |  | 51736<sup>(5)</sup> | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 51736 | $0 | 0 | I | By U.S. Venture Partners X, L.P.<sup>(6)</sup> |
| Convertible Promissory Note | $15.20 | 2025-08-11 |  | C |  |  | 1655<sup>(5)</sup> | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 1655 | $0 | 0 | I | By USVP X Affiliates, L.P.<sup>(6)</sup> |
| Convertible Promissory Note | $15.20 | 2025-08-11 |  | C |  |  | 16447<sup>(5)</sup> | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 16447 | $0 | 0 | D |  |
| Stock Option | $19 | 2025-08-07 |  | A |  | 47420 |  | <sup>(7)</sup> | 2035-08-07 | Common Stock | 47420 | $0 | 47420 | D |  |

---

### Footnotes:

(1) Each share of Series B-1 preferred stock and Series B-2 preferred stock automatically converted into approximately 0.4031 shares of Heartflow, Inc.'s ("Heartflow") common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

(2) Each share of Series C preferred stock automatically converted into approximately 0.5764 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

(3) Each share of Series D preferred stock automatically converted into approximately 0.6467 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

(4) Each share of Series F preferred stock automatically converted into approximately 0.3425 shares of Heartflow's common stock immediately prior to the closing of Heartflow's initial public offering. These shares are reported in Table II above on an as-converted basis.

(5) Upon the closing of Heartflow's initial public offering, the convertible promissory notes automatically converted into shares of Heartflow's common stock at a conversion price of 80% of the price per share in Heartflow's initial public offering, subject to a valuation ceiling of $2.0 billion. The shares of common stock that were issuable upon conversion of the convertible promissory note had no expiration date. These shares are reported in Table II above on an as-converted basis.

(6) Presidio Management Group X, L.L.C. ("PMG X") is the general partner of U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. The Reporting Person, Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Irwin Federman are the managing members of PMG X, and share voting and dispositive power with respect to the shares held by U.S. Venture Partners X, L.P. and USVP X Affiliates, L.P. Each of the managing members of PMG X disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

(7) The option will vest in full on the earlier of Heartflow's annual meeting of shareholders in 2026 and the first anniversary of the grant date, subject to continued service through such date.

**Signature:** /s/ Angela Ahmad, Attorney-in-Fact for Casey M. Tansey  
**Date:** 2025-08-11

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**